Levi & Korsinsky, LLP announces that a GDRX class action lawsuit has been commenced on behalf of investors who purchased GoodRx Holdings (GDRX) securities between September 23, 2020 and November 16, 2020. For more on the GoodRx Class Action please contact us today.
According to the GoodRx lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: at the time of the IPO, unbeknownst to investors, Amazon.com, Inc. was developing and would soon introduce its own online and mobile prescription medication ordering and fulfilment service that would directly compete with GoodRx. Defendants timed the IPO so that it was priced before Amazon announced its online pharmaceutical business to facilitate the IPO and create artificial demand for the common shares sold therein, as well to maximize the amount of money the Company and the selling stockholders could raise in the IPO. Given defendants’ knowledge of Amazon’s intention to enter the online pharmaceutical business, and their misleading statements about GoodRx’s competitive position made contemporaneously with that knowledge, defendants’ materially false and/or misleading statements alleged herein were made willfully and caused GoodRx common stock to trade at artificially inflated prices during the Class Period.
If you suffered a loss in GoodRx you have until February 16, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171